20:11 , Aug 1, 2018 |  BC Innovations  |  Distillery Techniques

Drug platforms

TECHNOLOGY: Gene therapy A method enabling BBB entry, and temporal and cell type-specific control of chemogenetic therapies could be used to develop treatments for CNS diseases. The method, dubbed acoustically targeted chemogenetics (ATAC), involves three steps:...
21:18 , Jul 31, 2018 |  BC Innovations  |  Translation in Brief

ATAC of the DREADDs

Scientists from the California Institute of Technology have combined ultrasound waves with gene and drug therapies to selectively and non-invasively control neural circuits. The approach could be used to treat neurologic and psychiatric diseases and...
18:22 , Jul 26, 2018 |  BC Innovations  |  Translation in Brief

A plasticity problem

New research from the University of Bordeaux suggests the synaptic pathology underlying Alzheimer’s disease is driven by aberrant activation of CAMK2 by β-amyloid oligomers. The findings may point to the missing link in how β-amyloid...
19:04 , Jun 6, 2018 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: Gene profiling A mutation in CAMK2A could help predict the risk of a previously undescribed neurodevelopmental disorder characterized by growth delay, frequent seizures and severe cognitive dysfunction. Genomic profiling of two children with the disease...
20:01 , Feb 1, 2018 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: January 2018

New Therapeutic Targets and Biomarkers: January 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during January 2018. Therapeutic targets are defined as any protein, gene or other molecule...
21:18 , Jan 23, 2018 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease; neurology

INDICATION: Multiple sclerosis (MS); pain Mouse studies suggest inhibiting CAMK2A could help treat MS, including MS-associated pain. In the experimental autoimmune encephalomyelitis (EAE) mouse model of MS, knock-in of an autophosphorylation-deficient CAMK2A variant or intrathecal injection...
22:57 , Nov 14, 2017 |  BC Innovations  |  Distillery Therapeutics

Cardiovascular

INDICATION: Hypertension Rat studies suggest inhibiting CAMK2 could help treat hypertension. In a rat model of hypertension, injection of a CAMK2 inhibitor tool peptide into the hypothalamic paraventricular nucleus decreased arterial blood pressure and sympathetic nerve...
19:01 , Oct 24, 2017 |  BC Innovations  |  Distillery Therapeutics

Cardiovascular

INDICATION: Atherosclerosis Patient sample and mouse studies suggest inhibiting CAMK2G could help treat atherosclerosis. In arterial plaque-associated macrophages from patients with carotid artery stenosis, levels of activated CAMK2G were higher in patients with stroke symptoms than...
21:16 , Feb 8, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Epilepsy Cell culture studies suggest inhibiting CAMK2 could help treat epilepsy. In a synaptic transmission assay in primary hippocampal pyramidal neurons from a mouse model of epilepsy, a CAMK2 inhibitor tool compound decreased persistent sodium...
08:00 , Jan 21, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Receptor-interacting serine-threonine kinase 3 (RIPK3; RIP3); calcium calmodulin-dependent protein kinase II (CAMK2)

Cardiovascular disease INDICATION: Heart failure Cell culture and mouse studies suggest inhibiting RIPK3 or CAMK2 could help treat heart failure. Levels of RIPK3 and RIPK3-phosphorylated CAMK2 were higher in rat ventricular myocytes under hypoxic conditions and doxorubicin-treated...